Loading...
Please wait, while we are loading the content...
Similar Documents
Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
| Content Provider | Scilit |
|---|---|
| Author | Drick, Nora Milger, Katrin Seeliger, Benjamin Fuge, Jan Korn, Stephanie Buhl, Roland Schuhmann, Maren Herth, Felix Kendziora, Benjamin Behr, Juergen Kneidinger, Nikolaus Bergmann, Karl-Christian Taube, Christian Welte, Tobias Suhling, Hendrik |
| Copyright Year | 2020 |
| Description | Background: Anti-IL-5 antibodies represent an established therapy for severe eosinophilic asthma (SEA), but some patients show inadequate response. The objective of this study was to assess the effects of a switch to anti-IL-5Rα therapy in patients with inadequate response to anti-IL-5 therapy. Methods: In this retrospective multi-centre, real-life study, we analysed all SEA patients switched from anti-IL-5 to anti-IL-5Rα therapy due to inadequate response or intolerability. Pulmonary function tests, blood gas analyses, asthma control tests (ACT) and oral corticosteroid (OCS) usage were analysed and compared at three timepoints: baseline (BL, before anti-IL-5 therapy), timepoint 1 (T1, under anti-IL-5 therapy) and timepoint 2 (T2, under anti-IL-5Rα therapy). Results: Of 665 patients treated with anti-IL-5 antibodies, 70 were switched to anti-IL-5Rα and 60 were included in the analysis. Median treatment duration was 8 months [IQR 5; 15] for anti-IL-5 and 5 months [IQR 4; 6] for anti-IL-5Rα therapy. $FEV_{1}$ was 61% of predicted at BL [IQR 41; 74], 61% [IQR 43; 79] at T1 and 68% [IQR 49; 87] at T2 $(p_{T1-T2}$=0.011). ACT score was 10 [IQR 8; 13], 16 [IQR 10; 19] and 19 [IQR 14; 22], respectively (both p< 0.001). The number of patients requiring OCS was reduced from 41 (BL) to 32 (T1) and 19 (T2) (both p< 0.001). Ten patients discontinued anti-IL-5Rα therapy due to insufficient efficacy (n=7) and adverse events (n=3). Conclusion: Switching from anti-IL-5 to anti-IL-5Rα therapy in patients with inadequate response was associated with significantly improved $FEV_{1}$, asthma control and OCS reduction. |
| Related Links | https://www.dovepress.com/getfile.php?fileID=63613 |
| Ending Page | 614 |
| Page Count | 10 |
| Starting Page | 605 |
| ISSN | 11786965 |
| DOI | 10.2147/jaa.s270298 |
| Journal | Journal of asthma and allergy |
| Volume Number | 13 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2020-11-01 |
| Access Restriction | Open |
| Subject Keyword | Respiratory System Benralizumab Eosinophils Mepolizumab Reslizumab Severe Asthma |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pulmonary and Respiratory Medicine Immunology and Allergy |
